Lördag 2 Augusti | 12:30:16 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-11-27 07:10 Kvartalsrapport 2025-Q3
2025-08-28 07:10 Kvartalsrapport 2025-Q2
2025-05-28 - Kvartalsrapport 2025-Q1
2025-03-28 - X-dag ordinarie utdelning FLUO 0.00 DKK
2025-03-27 - Årsstämma
2025-02-27 - Bokslutskommuniké 2024
2024-11-27 - Kvartalsrapport 2024-Q3
2024-08-29 - Kvartalsrapport 2024-Q2
2024-05-30 - Kvartalsrapport 2024-Q1
2024-03-21 - X-dag ordinarie utdelning FLUO 0.00 DKK
2024-03-20 - Årsstämma
2024-02-28 - Bokslutskommuniké 2023
2023-11-29 - Kvartalsrapport 2023-Q3
2023-08-30 - Kvartalsrapport 2023-Q2
2023-05-31 - Kvartalsrapport 2023-Q1
2023-03-22 - X-dag ordinarie utdelning FLUO 0.00 DKK
2023-03-21 - Årsstämma
2023-02-28 - Bokslutskommuniké 2022
2022-11-24 - Kvartalsrapport 2022-Q3
2022-08-25 - Kvartalsrapport 2022-Q2
2022-05-31 - Kvartalsrapport 2022-Q1
2022-05-19 - X-dag ordinarie utdelning FLUO 0.00 DKK
2022-05-18 - Årsstämma
2022-03-30 - Bokslutskommuniké 2021
2021-11-24 - Kvartalsrapport 2021-Q3
2021-08-25 - Kvartalsrapport 2021-Q2
2021-05-26 - Kvartalsrapport 2021-Q1
2021-05-03 - X-dag ordinarie utdelning FLUO 0.00 DKK
2021-02-26 - Bokslutskommuniké 2020
2021-02-09 - Årsstämma
2020-11-20 - Kvartalsrapport 2020-Q3
2020-08-14 - Kvartalsrapport 2020-Q2
2020-05-27 - Kvartalsrapport 2020-Q1
2020-04-09 - X-dag ordinarie utdelning FLUO 0.00 DKK
2020-04-08 - Årsstämma
2020-02-28 - Bokslutskommuniké 2019
2019-11-29 - Kvartalsrapport 2019-Q3
2019-05-31 - Kvartalsrapport 2019-Q1
2025-07-31 08:54:00

FluoGuide is advancing its position in head and neck cancer treatment. On 21 July 2025, the company announced a strategic collaboration with Olympus, a global med‑tech leader. The collaboration aims to jointly develop FG001 for tumor imaging and surgical margin assessment in head and neck cancer, focusing on the clinical phase and gathering evidence on Olympus’s imaging platforms.

FluoGuide now invites to two compelling presentations, where CEO Morten Albrechtsen will share insights into strategic opportunities that may accelerate the path to market - including collaborations with industry partners such as Olympus and Intuitive Surgical.

  • Thursday, 7 August 2025 - Redeye:
    A live-recorded interview with Morten Albrechtsen, CEO, conducted by Redeye analyst Christian Binder. The interview is scheduled for publication in the following days. Questions can be submitted in advance to Christian Binder (christian.binder@redeye.se) or IR@fluoguide.com. The interview will be in English. Link to the recording will be provided on FluoGuide and Redeye websites at distribution.
  • Friday, 8 August 2025 at 15:30 - 16.30 CEST:
    A live Q&A session with Morten Albrechtsen, CEO, moderated by Thomas Petersen. Questions can be submitted live during the event to Thomas Petersen or in advance to IR@fluoguide.com. The discussion will be in Danish.
    You can subscribe to the event here.


Expected takeaways from the presentations:

  • Partner strategy: How FluoGuide selects and builds strategic partnerships to accelerate market entry and create long-term value.
  • Long-term potential: What the partnerships mean for the commercialization of FG001 and expansion into other cancer indications.
  • Multiple partnerships: Why FluoGuide pursue a multi-partner approach.

FluoGuide looks forward to receiving your questions and to engaging in insightful discussions during the upcoming presentations.

Follow FluoGuide on LinkedIn: https://www.linkedin.com/company/fluoguide/
Sign up to receive FluoGuide news: https://fluoguide.com/investor/email-alerts/